Zung Thai, M.D., Ph.D., is a recognized leader in the field of oncology with an 18-year career as Chief Medical Officer and Oncology Development Lead at numerous companies, including Biotheryx, REMD, Atara, Gilead, Arresto, Anza, and Amgen. During his tenure at Biotheryx, Zung spearheaded all clinical and regulatory efforts for the BTX-A51 program. He has served as a Clinical Oncology Consultant to both big pharma and biotech startup companies and also played a pivotal role in the corporate acquisition of Arresto. Zung holds an A.B. from Cornell University and an M.D., Ph.D. from the University of Pittsburgh.